Sabcomeline

Sabcomeline (Memric; SB-202,026) is a selective M1 receptor partial agonist that was under development for the treatment of Alzheimer's disease.[1] It made it to phase III clinical trials before being discontinued due to poor results.

Sabcomeline
Clinical data
ATC code
  • None
Legal status
Legal status
  • Never marketed
Identifiers
IUPAC name
  • (3R)-N-methoxyquinuclidine-3-carboximidoyl cyanide hydrochloride
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC10H15N3O
Molar mass193.250 g·mol−1
3D model (JSmol)
SMILES
  • C2CC1CCN2CC1\C(\C#N)=N\OC

See also

References
  1. Loudon JM, Bromidge SM, Brown F, et al. (December 1997). "SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors". The Journal of Pharmacology and Experimental Therapeutics. 283 (3): 1059–68. PMID 9399977.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.